AdreView
Drug
GE HealthCare
Total Payments
$16,409
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $16,409 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,409 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ADR-16-01: Brain-Heart Connection in Takotsubo Cardiomyopathy | GE HealthCare | $16,409 | 0 |
Top Doctors Receiving Payments for AdreView
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $16,409 | 1 |
Ad
Manufacturing Companies
- GE HealthCare $16,409
Product Information
- Type Drug
- Total Payments $16,409
- Total Doctors 0
- Transactions 1
About AdreView
AdreView is a drug associated with $16,409 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is GE HealthCare.
Payment data is available from 2023 to 2023. In 2023, $16,409 was paid across 1 transactions to 0 doctors.
The most common payment nature for AdreView is "Unspecified" ($16,409, 100.0% of total).
AdreView is associated with 1 research study, including "ADR-16-01: Brain-Heart Connection in Takotsubo Cardiomyopathy" ($16,409).